Tirzepatide for weight loss: a complete guide
Tirzepatide is a dual GIP and GLP-1 receptor agonist that supports weight loss by activating two gut-hormone pathways that reduce appetite, slow stomach emptying, and increase fullness, so you eat less. Taken as a once-weekly injection with gradual dose increases, it is prescribed by a licensed provider alongside diet and activity changes.
What tirzepatide is and how it works
Tirzepatide is a dual receptor agonist: it activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Both are natural gut hormones involved in appetite and blood-sugar regulation. Acting on two pathways is what distinguishes tirzepatide from GLP-1-only medicines like semaglutide.
For weight management, tirzepatide reduces appetite, slows stomach emptying, and increases the feeling of fullness, which generally lowers calorie intake. It is used together with a reduced-calorie diet and increased physical activity, not as a replacement for them.
How it's taken and titration
Brand tirzepatide for weight management (Zepbound) is a once-weekly injection under the skin. Providers start at a low dose and increase it in steps over several weeks — titration — to help limit gastrointestinal side effects as the body adjusts.
Your provider sets your schedule and target dose based on your response and tolerance. Do not change your dose on your own; follow the instructions provided with your prescription.
Common side effects
The most common side effects are gastrointestinal and often lessen as your body adjusts:
- Nausea, vomiting, and diarrhea
- Constipation and abdominal pain
- Indigestion and decreased appetite
- Injection-site reactions, fatigue, or dizziness
Boxed warning and key contraindications
Tirzepatide carries an FDA boxed warning — the agency's most serious warning. In rodent studies it caused thyroid C-cell tumors; whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans is not known.
Because of this risk, tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also not be used by people with a known serious allergy to tirzepatide. Report symptoms such as a neck lump, trouble swallowing, hoarseness, or shortness of breath to a provider. Other serious risks reported include pancreatitis, gallbladder problems, and — in people with diabetes taking other glucose-lowering medicines — low blood sugar.
Who is and isn't a candidate
Dual GIP/GLP-1 weight-management medicines are generally considered for adults with obesity, or with overweight plus a weight-related condition, when clinically appropriate. A licensed provider reviews your full health history to decide whether treatment is suitable for you.
It is not appropriate for people with the contraindications above, and it is not used during pregnancy or while trying to become pregnant. Only a licensed provider can determine candidacy — this page is educational and does not establish that any treatment is right for you.
Compounded vs. brand tirzepatide
Brand tirzepatide products (Zepbound for weight management and Mounjaro for type 2 diabetes) are FDA-approved, meaning the FDA reviewed their manufacturing, safety, and effectiveness.
Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient. Compounded medications are NOT FDA-approved: the FDA does not review them for safety, effectiveness, or quality, and they are not a generic version of or a substitute for the brand product. A licensed provider decides whether any medication, brand or compounded, is appropriate and will explain the differences.
How is tirzepatide different from semaglutide?
Tirzepatide activates two receptors — GIP and GLP-1 — while semaglutide activates only the GLP-1 receptor. Both slow stomach emptying and reduce appetite. Which medicine, if any, is appropriate is a decision a licensed provider makes based on your health history.
Am I eligible for tirzepatide?
Eligibility is decided by a licensed provider who reviews your health history, current medications, and goals. These medicines are generally considered for adults with obesity, or overweight plus a weight-related condition, when clinically appropriate. This page can't determine eligibility for you.
How much weight can I expect to lose?
Results vary by person and depend on diet, activity, and adherence. In the SURMOUNT-1 clinical trial (Jastreboff et al., NEJM 2022), adults with obesity (without diabetes) taking once-weekly tirzepatide lost substantially more weight than those on placebo, alongside lifestyle changes. A trial average does not predict your individual result.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded tirzepatide is prepared by a licensed compounding pharmacy and is NOT FDA-approved — the FDA does not review it for safety, effectiveness, or quality. It is not a generic version of, or a substitute for, the brand products. A licensed provider will discuss which option, if any, is appropriate for you.
How do I get started with Medivive?
You start with a short conversation — not a quiz. Tell us about your goals in your own words, and if it looks like a potential fit, we connect you with a licensed provider who reviews your information and decides whether treatment is appropriate. No prescription is guaranteed.